Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO.
作者信息
Eijgelsheim Mark, Sprangers Ben
机构信息
Department of Nephrology, Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology, Rega Institute, Catholic University of Leuven, Leuven, Belgium; and.
出版信息
Kidney360. 2020 Feb 11;1(3):158-161. doi: 10.34067/KID.0001192019. eCollection 2020 Mar 26.
Abstract
摘要
相似文献
1
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO.应进行肾活检以明确免疫检查点抑制剂相关急性肾损伤的病因：支持观点。
Kidney360. 2020 Feb 11;1(3):158-161. doi: 10.34067/KID.0001192019. eCollection 2020 Mar 26.
2
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.应进行肾活检以明确免疫检查点抑制剂相关急性肾损伤的病因：评论
Kidney360. 2020 Feb 11;1(3):166-168. doi: 10.34067/KID.0001072019. eCollection 2020 Mar 26.
3
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON.应进行肾活检以明确免疫检查点抑制剂相关急性肾损伤的病因：反对意见。
Kidney360. 2020 Feb 11;1(3):162-165. doi: 10.34067/KID.0000132020. eCollection 2020 Mar 26.
4
Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events.免疫检查点抑制剂相关不良事件的肾移植中的基因表达谱分析。
Clin J Am Soc Nephrol. 2021 Sep;16(9):1376-1386. doi: 10.2215/CJN.00920121. Epub 2021 Jul 9.
5
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?免疫检查点抑制剂相关肾毒性：我们知道什么？我们应该做什么？
Kidney Int. 2020 Jan;97(1):62-74. doi: 10.1016/j.kint.2019.07.022. Epub 2019 Aug 23.
6
Short-term steroid therapy for immune-checkpoint-inhibitor-related acute kidney injury.免疫检查点抑制剂相关急性肾损伤的短期类固醇治疗
Int Urol Nephrol. 2024 Mar;56(3):1199-1200. doi: 10.1007/s11255-023-03734-7. Epub 2023 Aug 30.
7
Two acute kidney injury episodes after ICI therapy: a case report.免疫检查点抑制剂（ICI）治疗后发生 2 次急性肾损伤：病例报告。
CEN Case Rep. 2024 Oct;13(5):408-415. doi: 10.1007/s13730-024-00855-5. Epub 2024 Mar 7.
8
Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.免疫检查点抑制剂治疗转移性黑色素瘤患者致急性肾损伤的组织学诊断：一项回顾性病例系列报告。
BMC Nephrol. 2020 Sep 7;21(1):391. doi: 10.1186/s12882-020-02044-9.
9
Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.纳武利尤单抗免疫治疗转移性肾细胞癌后出现急性肾小管间质性肾炎和 IgM 在肾小球毛细血管壁沉积。
CEN Case Rep. 2020 Feb;9(1):48-54. doi: 10.1007/s13730-019-00424-1. Epub 2019 Oct 11.
10
Immune checkpoint inhibitors and acute kidney injury.免疫检查点抑制剂与急性肾损伤。
Front Immunol. 2024 Feb 23;15:1353339. doi: 10.3389/fimmu.2024.1353339. eCollection 2024.
引用本文的文献
1
External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis.基于电子健康记录的组织学急性肾小管间质性肾炎诊断模型的外部验证
J Am Soc Nephrol. 2025 May 1;36(5):859-868. doi: 10.1681/ASN.0000000556. Epub 2024 Nov 5.
2
Immune checkpoint inhibitors and acute kidney injury.免疫检查点抑制剂与急性肾损伤。
Front Immunol. 2024 Feb 23;15:1353339. doi: 10.3389/fimmu.2024.1353339. eCollection 2024.
3
New Challenges in the Diagnosis of Kidney Damage Due to Immune Checkpoint Inhibitors Therapy: An Observational Clinical Study.免疫检查点抑制剂治疗所致肾损伤诊断中的新挑战：一项观察性临床研究
Diagnostics (Basel). 2023 Jul 28;13(15):2524. doi: 10.3390/diagnostics13152524.
4
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.第一章：癌症药物治疗患者肾功能评估，选自 2022 年癌症药物治疗期间肾损伤管理临床实践指南。
Int J Clin Oncol. 2023 Oct;28(10):1259-1297. doi: 10.1007/s10147-023-02372-4. Epub 2023 Jun 29.
5
Acute Kidney Injury in Cancer Immunotherapy Recipients.癌症免疫治疗患者的急性肾损伤。
Cells. 2022 Dec 10;11(24):3991. doi: 10.3390/cells11243991.
6
'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injury.“预防胜于治疗”：对接受免疫检查点抑制剂治疗的患者联合用药的警示，以避免急性肾损伤。
Clin Kidney J. 2022 Jun 22;15(10):1803-1806. doi: 10.1093/ckj/sfac161. eCollection 2022 Oct.
7
Adverse Renal Effects of Anticancer Immunotherapy: A Review.抗癌免疫疗法的肾脏不良反应：综述
Cancers (Basel). 2022 Aug 23;14(17):4086. doi: 10.3390/cancers14174086.
8
Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?免疫疗法与肾病谱：我们是否应该个体化治疗？
Front Med (Lausanne). 2022 Jun 14;9:906565. doi: 10.3389/fmed.2022.906565. eCollection 2022.
9
Treatment of acute kidney injury in cancer patients.癌症患者急性肾损伤的治疗
Clin Kidney J. 2021 Dec 24;15(5):873-884. doi: 10.1093/ckj/sfab292. eCollection 2022 May.
10
Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond.免疫检查点抑制剂的肾毒性：急性肾损伤及其他影响
Cureus. 2020 Dec 21;12(12):e12204. doi: 10.7759/cureus.12204.
本文引用的文献
1
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者急性肾损伤的发生率、病因和危险因素。
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1692-1700. doi: 10.2215/CJN.00990119. Epub 2019 Oct 31.
2
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.在接受纳武单抗治疗转移性肾细胞癌后获得持久完全缓解的患者中观察到白癜风不良事件。
Front Oncol. 2019 Oct 9;9:1033. doi: 10.3389/fonc.2019.01033. eCollection 2019.
3
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.纳武利尤单抗治疗胃癌患者的免疫相关不良事件与预后的相关性。
BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y.
4
Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?转移性肾细胞癌患者中断纳武利尤单抗治疗后的持久缓解：肾毒性是预测纳武利尤单抗获益的标志物吗？
J Oncol Pharm Pract. 2020 Jun;26(4):1000-1004. doi: 10.1177/1078155219877923. Epub 2019 Oct 9.
5
Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.抗程序性死亡蛋白1（PD-1）免疫疗法可能会诱导间质性肾炎，并伴有肾小管上皮细胞中程序性死亡配体1（PD-L1）表达增加。
Kidney Int Rep. 2019 Jun 20;4(8):1152-1160. doi: 10.1016/j.ekir.2019.06.001. eCollection 2019 Aug.
6
Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients.两名晚期非小细胞肺癌患者在停止纳武单抗治疗后出现持久反应，且无疾病进展或毒性反应。
J Oncol Pharm Pract. 2020 Apr;26(3):761-767. doi: 10.1177/1078155219867131. Epub 2019 Aug 18.
7
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis.尿液 TNF-α 和 IL-9 用于急性间质性肾炎的临床诊断。
JCI Insight. 2019 May 16;4(10). doi: 10.1172/jci.insight.127456.
8
AKI in Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗患者的急性肾损伤
Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1077-1079. doi: 10.2215/CJN.02340219. Epub 2019 May 2.
9
Renal toxicities associated with pembrolizumab.与帕博利珠单抗相关的肾毒性。
Clin Kidney J. 2019 Feb;12(1):81-88. doi: 10.1093/ckj/sfy100. Epub 2018 Nov 9.
10
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.免疫检查点抑制剂的肾毒性：超越间质性肾炎。单中心经验。
J Immunother Cancer. 2019 Jan 6;7(1):2. doi: 10.1186/s40425-018-0478-8.
Zotero 插件